Comparative Pharmacology
Head-to-head clinical analysis: CRIXIVAN versus DESCOVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRIXIVAN versus DESCOVY.
CRIXIVAN vs DESCOVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indinavir is a specific, potent, reversible inhibitor of HIV-1 protease. It binds to the active site of the viral protease, preventing the cleavage of viral polyprotein precursors into functional proteins, resulting in the formation of immature, non-infectious virions.
DESCOVY is a fixed-dose combination of emtricitabine and tenofovir alafenamide. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine-5'-triphosphate and incorporating into viral DNA, causing chain termination. Tenofovir alafenamide is a prodrug of tenofovir, which is also an NRTI; it is taken up by cells and converted to tenofovir diphosphate, which inhibits HIV-1 reverse transcriptase via chain termination after incorporation into viral DNA.
800 mg orally every 8 hours on an empty stomach (1 hour before or 2 hours after meals) or with a light meal.
One tablet (emtricitabine 200 mg / tenofovir alafenamide 25 mg) orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is 1.8 to 2.5 hours in healthy adults; requires dosing every 8 hours.
TAF: 0.51 hours (intracellular tenofovir diphosphate ~150 hours). FTC: 10 hours (intracellular triphosphate >39 hours). Clinical context: Long intracellular half-life supports once-daily dosing.
Primarily fecal (78-82%) with approximately 20% renal excretion of unchanged drug.
Tenofovir alafenamide (TAF): 80% excreted renally as unchanged drug via glomerular filtration and active tubular secretion; 15% recovered in feces. Emtricitabine (FTC): 70% excreted renally as unchanged drug via glomerular filtration and active tubular secretion; 14% as metabolites; remainder in feces.
Category C
Category C
Antiretroviral
Antiretroviral